These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Removal of infected arteriovenous grafts is morbid and many patients do not receive a new access within 1 year. Cheng TW; Farber A; Eslami MH; Kalish JA; Jones DW; Rybin D; Siracuse JJ J Vasc Surg; 2019 Jul; 70(1):193-198. PubMed ID: 30591289 [TBL] [Abstract][Full Text] [Related]
16. Use of rifampin-soaked gelatin-sealed polyester grafts for in situ treatment of primary aortic and vascular prosthetic infections. Bandyk DF; Novotney ML; Johnson BL; Back MR; Roth SR J Surg Res; 2001 Jan; 95(1):44-9. PubMed ID: 11120634 [TBL] [Abstract][Full Text] [Related]
17. In situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience (1992 to 1998). Hayes PD; Nasim A; London NJ; Sayers RD; Barrie WW; Bell PR; Naylor AR J Vasc Surg; 1999 Jul; 30(1):92-8. PubMed ID: 10394158 [TBL] [Abstract][Full Text] [Related]
18. Outcomes of infected abdominal aortic grafts managed with antimicrobial therapy and graft retention in an unselected cohort. Maze MJ; Laws P; Buckenham T; Pithie A; Gallagher K; Metcalf S; Roake J; Chambers ST Eur J Vasc Endovasc Surg; 2013 Apr; 45(4):373-80. PubMed ID: 23485067 [TBL] [Abstract][Full Text] [Related]
19. Neoaortic Xenoprosthetic Grafts for Treatment of Mycotic Aneurysms and Infected Aortic Grafts. Anibueze C; Sankaran V; Sadat U; Tan K; Wilson YG; Brightwell RE; Delbridge MS; Stather PW Ann Vasc Surg; 2017 Oct; 44():419.e1-419.e12. PubMed ID: 28642109 [TBL] [Abstract][Full Text] [Related]
20. Risk factors and treatment outcomes for stent graft infection after endovascular aortic aneurysm repair. Shukuzawa K; Ohki T; Maeda K; Kanaoka Y J Vasc Surg; 2019 Jul; 70(1):181-192. PubMed ID: 30583901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]